BAKER BROS. ADVISORS LP 组合持仓
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001263508
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
Q1 2025 · 87 持仓数 · 申报总市值 $8.94B · 前十大集中度 82.7% · 更新于 2026-10-18
最后更新: 2026-10-18 · 来源: SEC EDGAR Form 13F-HR
换手率: 25.6% · 3 新建 · 11 减仓 · 8 清仓
主动份额(对标 S&P 500): 100.0% · 对比 QQQ: 100.0% — 组合中区别于指数权重的部分(越高越主动) · 排名
估算季度收益 (Q2 2026 → Q3 2026): +11.1% · 对比 SPY +9.0% · 上季市值 $19.13B — 按上季持仓市值以本季涨跌加权估算 · 排名
估算季内收益 (Q3 2026 → 最新收盘): -0.9% · 对比 SPY -3.1% · 最新申报市值 $20.65B — 最新申报持仓按季内至今涨跌加权(仍在变动) · 排名
在 Q1 2025 的 13F 申报中,BAKER BROS. ADVISORS LP 披露了 87 个股票持仓,合计申报市值 $8.94B。前十大持仓占申报市值的 82.7%,组合属于集中型。HoldingsHub 将其风格标签归纳为 Mid / Focused / Health Tilt / High Turnover。
截至 Q1 2025,最大的披露持仓包括 ONC($2.39B)、INCY($1.86B)、ACAD($712.20M)。行业分布上,占比最高的板块为 医疗保健 98.9%, 其他 1.1%。
与上一季度相比,BAKER BROS. ADVISORS LP 新建 3 个仓位、减持 11 个、清仓 8 个,换手率约 25.6%。持仓组合与上季度的重合率约为 86%。
Q1 2025 最大新建仓位为 VRNA($14.21M)、RGLS($4.71M)、SION($4.18M)。
较上季度清仓的 8 个仓位中,金额最大的是 KRYS($26.62M)、OPTEY($8.54M)、MIRM($7.88M)。
以上数据来自该基金的 SEC 13F 申报。13F 需在季度结束后 45 天内提交,仅涵盖 10 万美元以上的多头持仓,不含空头与非 13F 资产类别,因此本页反映的是季末快照,并非基金的实时持仓。
新建仓(Q1 2025)
- VRNA VERONA PHARMA PLC · $14.21M
- RGLS REGULUS THERAPEUTICS INC · $4.71M
- SION SIONNA THERAPEUTICS INC · $4.18M
- TECX TECTONIC THERAPEUTIC INC · $1.77M
完全清仓(较上季)
- KRYS KRYSTAL BIOTECH INC · 上季市值: $26.62M
- OPTEY OPTHEA LTD · 上季市值: $8.54M
- MIRM MIRUM PHARMACEUTICALS INC · 上季市值: $7.88M · 历史持仓
- ARVN ARVINAS INC · 上季市值: $7.77M
- BMEA BIOMEA FUSION INC · 上季市值: $5.63M
- ARCT ARCTURUS THERAPEUTICS HLDGS · 上季市值: $2.57M
- MRSN MERSANA THERAPEUTICS INC · 上季市值: $1.55M
- PTCT PTC THERAPEUTICS INC · 上季市值: $920.86K
内部人交易(Form 4)
BAKER BROS. ADVISORS LP 最新申报的 SEC Form 4 买卖——当该基金对某只股票的持股超过 10% 后,交易须在两个交易日内申报。
| 交易日期 | 交易方向 | 证券 | 股数 | 价格 | 申报 |
|---|---|---|---|---|---|
| 2026-11-06 | 买入 | MADRIGAL PHARMACEUTICALS, INC. | 2,000 | $396.61 | SEC 原文 |
| 2026-11-06 | 买入 | MADRIGAL PHARMACEUTICALS, INC. | 13,740 | $388.29 | SEC 原文 |
| 2026-11-06 | 买入 | MADRIGAL PHARMACEUTICALS, INC. | 60,400 | $383.01 | SEC 原文 |
| 2026-11-05 | 买入 | Kodiak Sciences Inc. | 81,729 | $98.51 | SEC 原文 |
| 2026-11-05 | 买入 | Kodiak Sciences Inc. | 4,703 | $98.51 | SEC 原文 |
| 2026-11-04 | 买入 | Kodiak Sciences Inc. | 151,916 | $98.51 | SEC 原文 |
| 2026-11-04 | 买入 | Kodiak Sciences Inc. | 8,742 | $98.51 | SEC 原文 |
| 2026-11-04 | 买入 | MADRIGAL PHARMACEUTICALS, INC. | 10,080 | $368.11 | SEC 原文 |
基金介绍
Baker BROS. Advisors 是在美国证券交易委员会(SEC)备案的 13F 申报机构,总部位于 New York, NY(美国)。截至 2026 年 Q3,其申报的美股持仓共 78 只,合计市值 $20.65B。本站收录其 13 个季度的申报记录(2023 年 Q3–2026 年 Q3)。
机构概况
- 总部:NEW YORK, NY(美国)
- SEC 注册编号:801-73446(状态:Approved),注册日期 2012-03-05
- 监管 AUM(Form ADV):$28.15B,截至 2026-03-27
- 客户结构(按监管 AUM):养老金计划 100%
- 管理私募基金 2 只(其中对冲基金 2 只)
持仓结构
- 78 只持仓 · 申报市值 $20.65B(2026 年 Q3)
- 前十大持仓占申报市值 78.7%
- 第一大持仓:INCY(INCYTE CORP),占 18.1%
- 平均每只持仓 $264.73M
行业偏好
- 医疗保健 99.9%
- (已分类持仓占申报市值 100%)
当季交易动作
- 2026 年 Q3:新建仓 3 只、加仓 6 只、减仓 11 只、清仓退出 8 只
- 持股数量不变的持仓 58 只
本段依据该机构公开的 SEC Form 13F 与 Form ADV 申报数据自动生成,仅陈述其申报事实,不构成对投资策略的评价或投资建议。
| # | 公司 | 股数 | 金额 | 权重 | Allocation | 变化 |
|---|---|---|---|---|---|---|
| 1 |
|
8.80M | $2.39B | 26.80% | 减持 | |
| 2 |
|
30.74M | $1.86B | 20.83% Form 4 · 1 → |
持有 | |
| 3 |
|
42.88M | $712.20M | 7.97% | 持有 | |
| 4 |
|
1.97M | $654.04M | 7.32% Form 4 · 5 → |
持有 | |
| 5 |
|
24.42M | $471.16M | 5.27% | 持有 | |
| 6 |
|
5.38M | $410.49M | 4.59% | 增持 | |
| 7 |
|
5.60M | $296.87M | 3.32% | 减持 | |
| 8 |
|
7.94M | $280.65M | 3.14% | 持有 | |
| 9 |
|
6.00M | $164.11M | 1.84% | 持有 | |
| 10 |
|
4.48M | $148.04M | 1.66% | 增持 | |
| 11 |
|
6.16M | $135.43M | 1.52% | 持有 | |
| 12 |
|
11.05M | $107.69M | 1.21% | 持有 | |
| 13 |
|
5.46M | $93.28M | 1.04% | 增持 | |
| 14 |
|
10.89M | $92.42M | 1.03% | 持有 | |
| 15 |
|
2.32M | $68.91M | 0.77% | 增持 | |
| 16 |
|
2.82M | $62.59M | 0.70% | 持有 | |
| 17 |
|
27.53M | $61.38M | 0.69% | 持有 | |
| 18 |
|
1.58M | $57.07M | 0.64% | 持有 | |
| 19 |
|
3.73M | $50.73M | 0.57% | 持有 | |
| 20 |
|
17.31M | $48.56M | 0.54% Form 4 · 86 → |
持有 | |
| 21 |
|
3.88M | $46.12M | 0.52% | 持有 | |
| 22 |
|
77.76K | $46.02M | 0.52% | 减持 | |
| 23 |
|
4.87M | $43.99M | 0.49% | 持有 | |
| 24 |
|
4.26M | $43.05M | 0.48% | 增持 | |
| 25 |
|
1.63M | $41.63M | 0.47% | 持有 | |
| 26 |
|
3.77M | $38.02M | 0.42% | 持有 | |
| 27 |
|
7.28M | $32.81M | 0.37% | 持有 | |
| 28 |
|
4.63M | $30.82M | 0.34% | 持有 | |
| 29 |
|
19.35M | $26.90M | 0.30% | 减持 | |
| 30 |
|
640.88K | $24.20M | 0.27% | 增持 | |
| 31 |
|
4.92M | $22.81M | 0.26% | 持有 | |
| 32 |
|
654.10K | $22.26M | 0.25% | 减持 | |
| 33 |
|
548.71K | $22.21M | 0.25% | 减持 | |
| 34 |
|
5.50M | $20.23M | 0.23% | 增持 | |
| 35 |
|
1.23M | $17.65M | 0.20% | 持有 | |
| 36 |
|
1.49M | $17.40M | 0.20% | 增持 | |
| 37 |
|
1.06M | $17.40M | 0.20% | 持有 | |
| 38 |
|
223.84K | $14.21M | 0.16% | 新进 | |
| 39 |
|
2.44M | $13.77M | 0.15% | 减持 | |
| 40 |
|
331.53K | $12.56M | 0.14% | 持有 | |
| 41 |
|
2.50M | $12.34M | 0.14% | 持有 | |
| 42 |
|
347.41K | $11.66M | 0.13% | 减持 | |
| 43 |
|
833.33K | $10.86M | 0.12% | 持有 | |
| 44 |
|
357.92K | $10.80M | 0.12% | 持有 | |
| 45 |
|
1.46M | $9.97M | 0.11% | 持有 | |
| 46 |
|
1.56M | $9.59M | 0.11% | 持有 | |
| 47 |
|
223.50K | $9.41M | 0.10% | 减持 | |
| 48 |
|
10.12M | $7.78M | 0.09% | 持有 | |
| 49 |
|
1.69M | $7.73M | 0.09% | 持有 | |
| 50 |
|
1.10M | $7.32M | 0.08% | 增持 | |
常见问题
What did BAKER BROS. ADVISORS LP buy in 2025-Q1?
In its 2025-Q1 13F filing, BAKER BROS. ADVISORS LP reported 87 equity positions worth $8.94B in aggregate; its largest disclosed positions were ONC ($2.39B), INCY ($1.86B), ACAD ($712.20M).
How large is BAKER BROS. ADVISORS LP's portfolio?
BAKER BROS. ADVISORS LP reported $8.94B of long equity holdings across 87 positions as of 2025-Q1. Top-10 holdings account for 82.7% of reported value.
What is BAKER BROS. ADVISORS LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.